Join
Live feed
·
PRReleasevia Quantisnow
Rain Enhancement Technologies Holdco Inc. logo

Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

ByQuantisnow·Wall Street's wire, on your screen.
RAIN· Rain Enhancement Technologies Holdco Inc.
Technology

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAIN (Rain Enhancement Technologies Holdco Inc.) and more on Quantisnow.